Instructions for Immard (hydroxychloroquine)
Russian Product Name
Immard®
English Product Name
Immard
Release Form
Coated tablets
Description Immard
Tablets coated with white or almost white film, round, biconvex, with "HCQS" engraved on one side.
1 tab
hydroxychloroquine sulfate 200 mg
[PRING] corn starch, calcium hydrophosphate, talc, silicon colloidal dioxide, polysorbate 80, magnesium stearate.
The composition of the shell: titanium dioxide, macrogol, hypromellose, talc.
ATX codes
P01BA02 Hydroxychloroquine
Clinical and pharmacological groups / Group affiliation
A derivative of 4-aminoquinoline. An anti-malarial and amebicide drug. Immunosuppressant
Active ingredient
hydroxychloroquine sulfate
Pharmacotherapeutic group Immard
Antimalarial
Retention conditions
The drug should be stored in a dry, light-protected place out of the reach of children at a temperature not exceeding 25 °C.
Expiration date
Shelf life - 2 years.
Pharmacological effect Immard
A drug against malaria that effectively targets RBCs (hematoschotropic activity). It stabilizes lysosomal membranes and prevents their enzymes from escaping, disrupting DNA replication, RNA synthesis, and hemoglobin processing by RBC forms of the parasite.
It also has immunosuppressive and anti-inflammatory properties, inhibits the formation of free radicals and reduces the activity of proteolytic enzymes (such as proteases and collagenases), and affects white blood cells and lymphocyte chemotaxis.
Testimony Immard
- malaria: Treat acute episodes and provide supportive therapy for malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium
- malariae (except hydroxychloroquine-resistant) and sensitive Plasmodium falciparum strains; definitive therapy for malaria caused by susceptible
- Plasmodium falciparum strains;
- Rheumatoid arthritis
- Systemic lupus erythematosus, discoid lupus erythematosus
- Photodermatosis
- Asthma
Method of use, course and dosage Immard
The drug is taken by mouth with food or a glass of milk.
200 mg hydroxychloroquine sulfate is equal to 155 mg hydroxychloroquine as a base.
For malaria, prophylaxis is given to adults 400 mg a day every 7 days; for children, the dose is 6.5 mg/kg weekly but, regardless of weight, the maximum dose should not exceed 400 mg. If possible, prophylaxis is begun 2 weeks before the estimated risk of infection. Otherwise, an initial double dose can be given, 800 mg for adults and 12.9 mg/kg for children (but not more than 800 mg), divided into two doses 6 hours apart. Prophylaxis should be continued for another 8 weeks after exiting an endemic area.
For acute malaria, adults are given 800 mg initially, then 400 mg at 6 to 8 hours, and 400 mg each on days 2 and 3 (total dose 2 g hydroxychloroquine sulfate). Alternatively, 800 mg may be given once.
For children, the total dose is 32 mg/kg (not to exceed 2 g) over 3 days.
Nosology Immard (ICD codes)
B50
Plasmodium falciparum malaria
B51
Plasmodium vivax malaria
B52
Plasmodium malariae malaria
B53.0
Plasmodium ovale malaria
J45
Asthma
L56.2
Photocontact dermatitis [berloque dermatitis]
L93.0
Discoid lupus erythematosus
M05
Seropositive rheumatoid arthritis
M32
Lupus erythematosus systemic
M35.0
Dry syndrome [Sjögren]
